GVAX vaccine for prostate cancer: Development restarted

BioSante restarted development of GVAX immunotherapy to treat prostate cancer and expects to begin a Phase

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE